These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 7791830)

  • 21. Outrunning HIV to protect immune defenses.
    Gilden D
    GMHC Treat Issues; 1996 Nov; 10(11):1-5. PubMed ID: 11364008
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interleukin-2: trials and tribulations.
    Kuritzkes DR
    J Infect Dis; 2009 Jul; 200(2):164-5. PubMed ID: 19508158
    [No Abstract]   [Full Text] [Related]  

  • 23. Improved treatment results with interleukin-2.
    HIV Hotline; 1998 May; 8(2):13-4. PubMed ID: 11365363
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
    Tavel JA; Sereti I; Walker RE; Hahn B; Kovacs JA; Jagannatha S; Davey RT; Falloon J; Polis MA; Masur H; Metcalf JA; Stevens R; Rupert A; Baseler M; Lane HC
    J Infect Dis; 2003 Aug; 188(4):531-6. PubMed ID: 12898439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
    Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
    Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Approaches to immune reconstitution in HIV infection.
    Napolitano LA
    Top HIV Med; 2003; 11(5):160-3. PubMed ID: 14555803
    [No Abstract]   [Full Text] [Related]  

  • 27. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients.
    Lévy Y; Gahéry-Ségard H; Durier C; Lascaux AS; Goujard C; Meiffrédy V; Rouzioux C; El Habib R; Beumont-Mauviel M; Guillet JG; Delfraissy JF; Aboulker JP;
    AIDS; 2005 Feb; 19(3):279-86. PubMed ID: 15718838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Honing the immune attack on HIV.
    Gilden D
    GMHC Treat Issues; 1996 Dec; 10(12):8-11. PubMed ID: 11364019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of HIV-infected patients with intermittent interleukin-2: effects of cycle frequency and cycle duration on degree of CD4(+) T-lymphocyte expansion.
    Miller KD; Spooner K; Herpin BR; Rock-Kress D; Metcalf JA; Davey RT; Falloon J; Kovacs JA; Polis MA; Walker RE; Masur H; Lane HC
    Clin Immunol; 2001 Apr; 99(1):30-42. PubMed ID: 11286539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Human immunodeficiency virus infection: physiopathological approach to specific therapeutic strategies].
    Clumeck N
    Rev Med Brux; 1996 Sep; 17(4):164-6. PubMed ID: 8927838
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV therapy in the post-eradication era.
    Vella S; Palmisano L
    J Biol Regul Homeost Agents; 2000; 14(1):34-7. PubMed ID: 10763890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-2.
    Linnemeyer PA
    STEP Perspect; 1995; 7(1):6-7. PubMed ID: 11362400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IL-2 restores immune sytem.
    Grodeck B
    Posit Aware; 1995; ():8. PubMed ID: 11362384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-2 clinical trials.
    Newsline People AIDS Coalit N Y; 1998 Sep; ():58. PubMed ID: 11367495
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NIH launches interleukin-2 study.
    AIDS Patient Care STDS; 1998 Jan; 12(1):68. PubMed ID: 11361897
    [No Abstract]   [Full Text] [Related]  

  • 36. IL-2 therapy provides no clinical benefit to HIV-infected patients on ART.
    Clin Infect Dis; 2009 Apr; 48(8):iii. PubMed ID: 19301459
    [No Abstract]   [Full Text] [Related]  

  • 37. IL-2 for HIV: the long march toward FDA approval. Food and Drug Administration.
    Sterritt C
    GMHC Treat Issues; 1997 Sep; 11(9):1-3. PubMed ID: 11364749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of multidrug resistant primary HIV infection with delayed CD4 T-cell count decline despite low viral load, treated with interleukin-2.
    Pao D; Smit E; Imami N; Fisher M
    AIDS; 2006 Jul; 20(11):1564-5. PubMed ID: 16847417
    [No Abstract]   [Full Text] [Related]  

  • 39. HAART and IL-2.
    AIDS Patient Care STDS; 2001 Jan; 15(1):54. PubMed ID: 11265652
    [No Abstract]   [Full Text] [Related]  

  • 40. Applying viral load measurements to HIV care.
    Klaus BD
    Nurse Pract; 1996 Aug; 21(8):102-4. PubMed ID: 8871994
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.